Old West Investment Management LLC Has $3.64 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Old West Investment Management LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 617.2% during the 3rd quarter, Holdings Channel reports. The firm owned 340,441 shares of the biopharmaceutical company’s stock after purchasing an additional 292,976 shares during the period. Amicus Therapeutics makes up 1.3% of Old West Investment Management LLC’s holdings, making the stock its 24th largest holding. Old West Investment Management LLC’s holdings in Amicus Therapeutics were worth $3,636,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in FOLD. Janus Henderson Group PLC grew its position in Amicus Therapeutics by 20.1% during the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after buying an additional 2,307,385 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Amicus Therapeutics by 583.4% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company’s stock worth $25,640,000 after purchasing an additional 1,858,100 shares during the period. Millennium Management LLC raised its stake in Amicus Therapeutics by 1,758.9% in the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock valued at $18,790,000 after purchasing an additional 1,792,277 shares in the last quarter. William Blair Investment Management LLC lifted its position in Amicus Therapeutics by 12.8% during the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock worth $128,993,000 after purchasing an additional 1,477,084 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in Amicus Therapeutics by 141.1% during the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock worth $21,765,000 after buying an additional 1,192,489 shares in the last quarter.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $10,382,718.34. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 22,500 shares of company stock worth $253,275. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $12.50 on Wednesday. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. The stock has a market cap of $3.71 billion, a PE ratio of -30.10 and a beta of 0.68. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The business has a 50-day simple moving average of $11.15 and a two-hundred day simple moving average of $10.60.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The company had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. The firm’s revenue was up 34.0% compared to the same quarter last year. Analysts anticipate that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on FOLD. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price objective on the stock. Bank of America upped their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. decreased their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 16th. Finally, Morgan Stanley dropped their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.13.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.